logo

Mymd Pharmaceuticals, Inc. (MYMD)



Trade MYMD now with
  Date
  Headline
11/14/2022 8:19:51 AM MyMD Announces Publication Of Phase 1 Data For Oral TNF-alpha Inhibitor MYMD-1 In Peer-Reviewed Journal Drug Research
9/20/2022 8:09:55 AM MyMD Pharma Provides Dosing Update On Phase 2 Multi-Center Clinical Trial Of MYMD-1
8/30/2022 8:37:47 AM MyMD Pharma Receives Grant From European Patent Office For Supera-CBD Compound
7/26/2022 7:35:53 AM MyMD Advances Phase 2 Trial Of MYMD-1 As Therapy For Delaying Aging And Extending Healthy Lifespan
6/21/2022 10:35:29 AM MyMD Advances Phase 2 Clinical Trial Of MYMD-1 As Therapy For Delaying Aging And Extending Healthy Lifespan
4/5/2022 9:17:41 AM MyMD Accelerates Pace Of New Patient Dosing In Phase 2 Trial Of MYMD-1 As Therapy For Delaying Aging
2/23/2022 9:18:32 AM MyMD Enrolls First Patient In Phase 2 Trial Of MYMD-1 As Therapy For Delaying Aging And Extending Healthy Lifespan
2/8/2022 9:29:11 AM MyMD Reports Positive Clinical Data In Advance Of Upcoming Phase 2 Trial Of MYMD-1 For Extending Healthy Lifespan
11/16/2021 9:28:16 AM MyMD Pharmas Receives FDA IND Clearance To Begin Phase 2 Trial Of MYMD-1 For Extending Healthy Lifespan
9/22/2021 11:06:23 AM MyMD Announces Data Demonstrating 8,000 Times Higher Potency Of Novel Synthetic Supera-CBD Over Plant-Derived CBD